New Analyses From a Large Randomized Screening Trial
A fresh paper in Nature Medicine presents secondary endpoint analyses from the NHS-Galleri randomized controlled trial, a major study built around a multi-cancer early detection (MCED) blood test delivered inside the English National Health Service. The article was published online on 22 September 2026 under DOI 10.1038/s41591-026-04652-8, and its focus is explicitly on secondary endpoints rather than the trial's headline primary comparison.
That distinction matters. In a randomized controlled trial, the primary endpoint is the single measure chosen in advance to answer the central question. Secondary endpoints are the additional measurements that help researchers understand how and why an intervention behaves the way it does. Publishing those analyses separately is a normal part of the scientific process, but it also means readers should treat the findings as parts of a larger picture rather than as standalone verdicts.
What the Trial Was Built to Test
The NHS-Galleri trial was designed to examine whether adding an MCED blood test to existing cancer screening pathways could shift the stage at which cancers are found. The underlying idea is straightforward: many cancers are far more treatable when detected early, yet most current screening programs target only a handful of cancer types, such as breast, cervical, bowel and lung cancer. A test capable of flagging multiple cancer signals from a single blood draw could, in principle, widen that net considerably.
Because the study was randomized, participants were allocated to different arms rather than choosing their own path. Randomization is the backbone of reliable medical evidence. It limits the risk that people who seek out a new test differ systematically from those who do not — a problem that can make observational screening data misleading. By comparing otherwise similar groups over time, the trial can separate the effect of the test from the effect of being the kind of person who volunteers for screening.
Why Secondary Endpoints Get Their Own Paper
Secondary endpoint analyses in screening trials typically explore several different dimensions at once. They may examine how the test behaved across different participant subgroups, how many participants returned for follow-up testing, what kinds of downstream investigations were triggered, or how the performance of the test looked when measured in ways that differ from the primary analysis plan.
These questions are not peripheral trivia. A screening test that finds more cancers but generates a large volume of unnecessary follow-up procedures can create real harm, including anxiety, invasive diagnostic work, and pressure on imaging and pathology services. A test that performs unevenly across age groups or in people with other health conditions raises questions about who should receive it. Secondary analyses are where much of that nuance surfaces.
The Broader Context of Multi-Cancer Early Detection
MCED tests sit at the intersection of oncology, genomics and health policy, which is why the NHS-Galleri results attract attention well beyond the research community. Most approaches in this field look for biological traces that tumors shed into the bloodstream, then use computational models to decide whether those traces warrant further investigation. The promise is a single, minimally invasive test; the difficulty is achieving enough accuracy to be useful without overwhelming health systems with false alarms.
- Sensitivity: the ability to correctly identify people who do have cancer, including at early stages when signals can be faint.
- Specificity: the ability to correctly clear people who do not have cancer, since false positives trigger real procedures.
- Positive predictive value: how often a positive result actually corresponds to a cancer, which depends heavily on how common cancer is in the tested population.
- Clinical utility: whether using the test actually improves outcomes such as stage at diagnosis or survival, rather than merely detecting more disease.
That last point is the hardest to establish and the reason randomized trials take years to complete. Detecting a cancer earlier only helps if earlier detection changes what happens to the patient. Some tumors grow so slowly that they would never have caused harm during a person's lifetime, and finding them can lead to treatment that offers no benefit. This phenomenon, known as overdiagnosis, is a central concern in every cancer screening debate.
Reading Secondary Analyses Carefully
Because this publication covers secondary endpoints, it should be read alongside the trial's primary results rather than in isolation. Secondary analyses are often described in the literature as hypothesis-generating: they can reveal patterns worth pursuing, suggest which subgroups deserve closer study, and inform how a test might eventually be deployed. They are generally not designed with the same statistical power as the primary endpoint, and researchers typically caution against drawing definitive conclusions from them.
For clinicians and policymakers, the practical questions are familiar ones. Does the evidence justify offering an MCED test to a broad population? Who should pay for it? What happens when a result comes back positive and no tumor can be located? How are results communicated to people who may reasonably assume that a negative test means they are cancer-free? The NHS-Galleri trial exists precisely because those questions cannot be answered by laboratory performance alone.
What Comes Next
The publication of secondary endpoint analyses signals that the research team is working through the trial's data in depth, examining the mechanisms behind the headline numbers and stress-testing the findings from multiple angles. As further analyses and the primary outcome data are reported, the picture will sharpen. Until then, the honest summary is that this is one more substantial piece of evidence in an ongoing evaluation — valuable for specialists, but not on its own a final answer about whether multi-cancer early detection is ready for routine use.
Developments Today will continue to follow the NHS-Galleri trial and the wider MCED field as results accumulate.
This article is based on reporting by Nature Medicine. Read the original article.
Originally published on nature.com
